W.L. Gore & Associates, Inc. And Gore Enterprise Holdings, Inc. v. C.R. Bard, Inc.

977 F.2d 558, 117 A.L.R. Fed. 827, 24 Fed. R. Serv. 3d 429, 24 U.S.P.Q. 2d (BNA) 1451, 1992 U.S. App. LEXIS 26007, 1992 WL 280385
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 14, 1992
Docket91-1305
StatusPublished
Cited by41 cases

This text of 977 F.2d 558 (W.L. Gore & Associates, Inc. And Gore Enterprise Holdings, Inc. v. C.R. Bard, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
W.L. Gore & Associates, Inc. And Gore Enterprise Holdings, Inc. v. C.R. Bard, Inc., 977 F.2d 558, 117 A.L.R. Fed. 827, 24 Fed. R. Serv. 3d 429, 24 U.S.P.Q. 2d (BNA) 1451, 1992 U.S. App. LEXIS 26007, 1992 WL 280385 (Fed. Cir. 1992).

Opinions

PAULINE NEWMAN, Circuit Judge.

C.R. Bard, Inc. appeals the order of the United States District Court for the District of New Jersey 1, declining to modify an injunction previously entered by consent, based on settlement between the parties. Bard urges that the law upon which the injunction was predicated has now been changed, and that it would be unfair to hold Bard to the original terms of the settlement. We affirm the district court’s denial of the requested modification.

BACKGROUND

In February, 1984 W.L. Gore & Associates and Gore Enterprise Holdings (collectively “Gore”) sued Bard for infringement of United States Patent No. 4,187,390 entitled “Porous Products and Process Therefor”, inventor Robert W. Gore. The patent expires in April, 1993. The Gore patent is directed to a porous polytetrafluoroethy-lene (PTFE) material that Gore sells under the GORE-TEX brand name. Gore has sold vascular prostheses (synthetic blood vessels) made of its PTFE material since 1975. The Bard products that were accused of infringement were vascular prostheses made of PTFE, which had been approved by the Food and Drug Administration based on Bard’s representation that its products were “substantially equivalent” to those of Gore.

The parties settled the lawsuit. Bard agreed, inter alia, to be enjoined from “infringing or actively inducing infringement” of the Gore patent. Paragraph 4 of the order of Final Judgment and Injunction on Consent, entered by the district court on April 12, 1984, provides:

4. Bard, its officers, agents, servants, employees, attorneys and those persons in active concert or participation with them who receive actual notice of the order by personal service or otherwise, are hereby enjoined and restrained from infringing or actively inducing infringement of one or more of Claims 9, 12, 16, 35 and 36 of United States Letters Patent No. 4,187,390 including, without limi[560]*560tation, the manufacture and/or use and/or sale and/or the promotion of sale and/or use of products heretofore identified as “Bard PTFE Reinforced Expanded PTFE Vascular Prosthesis” or as “Bard Blood Access PTFE Vascular Prosthesis”.

The consent judgment provides that the district court “shall retain jurisdiction over the parties and over the subject matter of this action for the purpose of insuring compliance with the injunction provided by-paragraph 4 hereof.”

On April 23, 1984 the Federal Circuit held in Roche Products, Inc. v. Bolar Pharmaceutical Co., 733 F.2d 858, 221 USPQ 937 (Fed.Cir.), cert. denied, 469 U.S. 856, 105 S.Ct. 183, 83 L.Ed.2d 117 (1984), that since it was patent infringement to make, use, or sell a patented product, no exception pertained when the purpose of the activity was to develop information for use in obtaining Federal regulatory approval of a drug. This holding was overturned by act of Congress in September, 1984 with the addition of subsection 271(e):

35 U.S.C. § 271(e).
(1) It shall not be an act of infringement to make, use, or sell a patented invention ... solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products....
******
(3) In any action for patent infringement brought under this section, no in-junctive or other relief may be granted which would prohibit the making, using, or selling of a patented invention under paragraph (1).

Interpreting § 271(e), the Supreme Court in Eli Lilly and Co. v. Medtronic, Inc., 496 U.S. 661, 110 S.Ct. 2683, 110 L.Ed.2d 605, 15 USPQ2d 1121 (1990) held that the terminology “drugs” encompasses medical devices.

Following the Eli Lilly decision Bard sought, pursuant to Fed.R.Civ.P. 60(b),2 modification of the settlement agreement to authorize Bard to engage in activity reasonably related to Federal regulatory approval of its new prostheses. Bard asked the district court to add the following text to paragraph 4 of the consent judgment:

... except that Bard may make, use, or sell articles which would otherwise infringe United States Letters Patent No. 4,187,390 so long as such making, using, or selling is solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs or veterinary biological products, as permitted under 35 U.S.C. § 271(e)(1).

The district court denied the request, holding that Bard had not made a sufficient showing of extreme and unexpected hardship or other basis of modification of a voluntary settlement agreement.

DISCUSSION

A

The Supreme Court has “long recognized that ‘[pjublic policy dictates that there be an end of litigation; that those who have contested an issue shall be bound by the result of the contest, and that matters once tried shall be considered forever settled as between the parties.’ ” Federated Department Stores, Inc. v. Moitie, 452 U.S. 394, 401, 101 S.Ct. 2424, 2429, 69 L.Ed.2d 103 (1981) (quoting Baldwin v. Traveling Men’s Association, 283 U.S. 522, 525, 51 S.Ct. 517, 518, 75 L.Ed. 1244 (1931)). The consent order embodying the settlement between Gore and Bard is a final judgment; it is accompanied by finality as stark as an adjudication after full trial. See Delaware Valley Citizens’ Council v. Commissioner of Pennsylvania, 674 F.2d 976, 981 (3d Cir.), cert. denied, 459 U.S. 905, 103 S.Ct. 206, 74 L.Ed.2d 165 (1982).

[561]*561When litigation is ended by the deliberate choice of the parties, a movant’s burden for modification of a consent order is particularly heavy, United States Steel Corp. v. Fraternal Association of Steel Haulers, 601 F.2d 1269, 1274 (3d Cir.1979), for "while consent decrees are judicial acts, they have often been recognized as having many of the attributes of a contract voluntarily undertaken.” Philadelphia Welfare Rights Organization v. Shapp, 602 F.2d 1114, 1119-20 (3d Cir.1979), cert. denied, 444 U.S. 1026, 100 S.Ct. 689, 62 L.Ed.2d 660 (1980). As the Third Circuit remarked,3 when parties have chosen to submit to a consent decree instead of seeking a more favorable judgment upon litigation, “their burden under Rule 60(b) is perhaps even more formidable than had they litigated and lost.” Id. at 1120.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Brown
547 B.R. 846 (S.D. California, 2016)
ePlus Inc. v. Lawson Software, Inc.
946 F. Supp. 2d 459 (E.D. Virginia, 2013)
Mojica v. Secretary of Health & Human Services
102 Fed. Cl. 96 (Federal Claims, 2011)
Infiniti Information Solutions, LLC v. United States
93 Fed. Cl. 699 (Federal Claims, 2010)
Phelps v. Alameida
569 F.3d 1120 (Ninth Circuit, 2009)
Deg, LLC v. Township of Fairfield
966 A.2d 1036 (Supreme Court of New Jersey, 2009)
CNA Corp. v. United States
83 Fed. Cl. 1 (Federal Claims, 2008)
Louisville Bedding Company v. Pillowtex Corporation
455 F.3d 1377 (Federal Circuit, 2006)
Sinclair Oil Corporation v. Abraham
291 F.3d 822 (Federal Circuit, 2002)
Talasila, Inc. v. United States
36 F. App'x 430 (Federal Circuit, 2002)
Sinclair Oil Corp. v. Abraham
291 F.3d 822 (Federal Circuit, 2002)
Brickwood Contractors, Inc. v. United States
49 Fed. Cl. 738 (Federal Claims, 2001)
In Re Midlands Utility, Inc.
253 B.R. 683 (D. South Carolina, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
977 F.2d 558, 117 A.L.R. Fed. 827, 24 Fed. R. Serv. 3d 429, 24 U.S.P.Q. 2d (BNA) 1451, 1992 U.S. App. LEXIS 26007, 1992 WL 280385, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wl-gore-associates-inc-and-gore-enterprise-holdings-inc-v-cr-cafc-1992.